Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LFMD
#3191
LifeMD, Inc. Common Stock
2.6
7
-2.91%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
-2.91%
Monthly Change
-24.79%
6 month change
-58.86%
Cambio anual
-46.06%
Cierres anteriores
2.7
5
Open
2.6
7
Bid
Ask
Low
2.6
7
High
2.6
7
Volumen
41
Markets
Acciones
Atención Sanitaria
LFMD
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Total assets
72.56 M
72.46 M
73.61 M
73.56 M
65.98 M
Total liabilities
78.51 M
76.51 M
74.01 M
73.18 M
62.62 M
Total equity
-5.96 M
-4.05 M
-392.75 K
382.38 K
3.37 M
Total liabilities & shareholders' equities
72.56 M
72.46 M
73.61 M
73.56 M
65.98 M
Total debt
—
—
—
—
—
Net debt
—
—
—
—
—
LifeMD Inc
LifeMD, Inc. is a publicly traded American telehealth company. It gives subscribers access to doctors and nurse practitioners for virtual medical consultations and treatments with prescription medications.
Noticias
Hims & Hers Expands Digital Health and Global Platform Strategy
LifeMD: Still My Favorite Bargain On The Market (NASDAQ:LFMD)
LifeMD: Pure Telehealth Play With In-House Pharmacy Integration (NASDAQ:LFMD)
BMO Capital raises Novo Nordisk stock price target to $57 on market outlook
Hims & Hers Scales Platform-Led Digital Healthcare Access and Care
Jefferies baja calificación de GoodRx a Mantener por desafíos en segmento de recetas
Jefferies rebaja la calificación de GoodRx a Mantener debido a desafíos en el segmento de recetas
Hims & Hers And HIMZ: Short‑Term Pain From Novo, Long‑Term Opportunity Still Bright (HIMS)
BMO Capital mantiene el precio objetivo de Novo Nordisk en 46 dólares
Novo Nordisk stock price target maintained at $46 by BMO Capital
LifeMD mantiene calificación de Compra en H.C. Wainwright tras lanzar píldora Wegovy
LifeMD mantiene calificación de Compra en H.C. Wainwright tras lanzamiento de píldora Wegovy